Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis

Journal of Viral Hepatitis

Volumn 24, Issue 10, 2017, Pages 858-864

  Vukotic, R ^a   Conti, F ^a   Fagiuoli, S ^b   Morelli, M C ^a   Pasulo, L ^b   Colpani, M ^b   Foschi, F G ^c   Berardi, S ^a   Pianta, P ^a   Mangano, M ^a   Donato, M F ^d   Malinverno, F ^d   Monico, S ^d   Tame M ^a   Mazzella, G ^a   Belli, L S ^e   Vigano R ^e   Carrai, P ^f   Burra, P ^g   Russo, F P ^g   Lenci, I ^h   Toniutto, P ⁱ   Merli, M ^j   Loiacono, L ^k   Iemmolo, R ^l   Degli Antoni, A M ^m   Romano, A ^g   Picciotto, A ⁿ   Rendina, M ^o   Andreone, P ^a   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^c UOC di Pediatria e Neonatologia AUSL Della Romagna   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f UNIVERSITY OF PISA   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

ⁱ UNIVERSITY OF UDINE   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^l ASL Modena Centro   (Italy)

^m UO Chirurgia d' Urgenza   (Italy)

ⁿ UNIVERSITY OF GENOA   (Italy)

^o UNIVERSITY OF BARI   (Italy)

more..

Author keywords

antiviral therapy; fibrosing cholestatic hepatitis; liver transplant; long term outcome; severe hepatitis C virus recurrence

Indexed keywords

DACLATASVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHILD PUGH SCORE; CHOLESTATIC HEPATITIS; COHORT ANALYSIS; COMBINATION DRUG THERAPY; DISEASE SEVERITY; FIBROSING CHOLESTATIC HEPATITIS; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONG TERM CARE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECURRENT INFECTION; REOPERATION; SURVIVAL RATE; SURVIVOR; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS; KAPLAN MEIER METHOD; LIVER FUNCTION TEST; MIDDLE AGED; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS; HEPATITIS C; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85018368155     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12712     Document Type: Article

References (23)

1. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35:680-687.
2. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 2006;12:1192-1204.
3. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008;14(Suppl 2):S36-S44.
4. Blasco A, Forns X, Carrion JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006;43:492-499.
5. Crespo G, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012;142:1373-1383.
6. Guido M, Fagiuoli S, Tessari G, et al. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut. 2002;50:697-700.
7. Vasuri F, Malvi D, Gruppioni E, Grigioni WF, D'Errico-Grigioni A. Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review. World J Gastroenterol. 2014;20:2810-2824.
8. Verna E, Abdelmessih R, Salomao MA, Lefkowitch J, Moreira RK, Brown RS Jr. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl. 2013;19:78-88.
9. Doughty A, Painter D, McCaughan G. Posttransplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to HCV. J Hepatol. 2000;32:126-134.
10. Ponziani FR, Viganò R, Iemmolo RM, et al. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. Dig Liver Dis. 2014;46:440-445.
11. Price JC, Terrault NA. Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in. Liver Transpl. 2015;21:423-434.
12. Gambato M, Lens S, Navasa M, Forns X. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol. 2014;61(1 Suppl):S120-S131.
13. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375-2382.
14. Gutierrez JA, Carrion AF, Avalos D, et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl. 2015;21:823-830.
15. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148:108-117.
16. Pellicelli AM, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis. 2014;46:923-927.
17. Pungpapong S, Aqel B, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015;61:1880-1886.
18. Saab S, Greenberg A, Li E, et al. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int. 2015;35:2442-2447.
19. Leroy V, Dumortier J, Coilly A, et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol. 2015;13:1993-2001.
20. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649-659.
21. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61:1485-1494.
22. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016;63:1493-1505.
23. Martini S, Sacco M, Strona S, et al. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis. Liver Int. 2016;37:62-70.